Abingen Biotech

Abingen Biotech is a preclinical-stage biopharmaceutical company specialized in the discovery and development of next-generation antibody therapeutics for cancer and inflammatory diseases. The company utilizes a proprietary engineering platform to create "bio-responsive" or conditionally active antibodies designed to trigger therapeutic action specifically within the tumor microenvironment while remaining inactive in healthy tissues. Their lead program focuses on the CD47 pathway, seeking to overcome the hematological toxicities associated with first-generation CD47 inhibitors. By enhancing the safety and therapeutic window of immune-modulating agents, Abingen aims to provide more effective treatments for both solid and liquid tumors.